Patent ID: 8563610

Claim:
A method for the diagnosis of oxidative stress related disorders in a subject comprising: (a) collecting a sample of urine from the subject; (b) determining the level of polyunsaturated fatty acid metabolites selected from the group consisting of neuroprostanes and resolvins present in the urine; and (c) normalizing the level of polyunsaturated fatty acid metabolites present in the urine to urinary creatinine to obtain a normalized level of polyunsaturated fatty acid metabolites, wherein a normalized level of polyunsaturated fatty acid metabolites above a predetermined amount is indicative of an oxidative stress related disorder and the oxidative stress disorder is selected from the group consisting of autism, Alzheimer's disease, asthma, Huntington's disease, atherosclerosis, hepatorenal syndrome, scleroderma, cardiac/renal ischemia/reperfusion injury, coronary angioplasty, Selenium deficiency, Vitamin W deficiency, organophosphate poisoning, hyperhomocysteinemia, renal transplant dysfunction, smoking, diabetes, rhabdomyolysis, bile duct obstruction, O 2 pulmonary toxicity in premature infants, halothane hepatotoxicity, acetaminophen poisoning, age-related decline in renal function, Cr (VI) poisoning, retinopathy of the newborn, alcohol ingestion paraquat poisoning, cisplatin-induced renal dysfunction, neuro-developmental disorders, inflammatory bowel disorder, Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), bronchopulmonary dysplasia (BPD), arthritis, and periodontal disease.